GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:003164716 | Endometrium | AEH | regulation of protein stability | 77/2100 | 298/18723 | 1.13e-12 | 2.26e-10 | 77 |
GO:000989616 | Endometrium | AEH | positive regulation of catabolic process | 104/2100 | 492/18723 | 9.38e-11 | 1.10e-08 | 104 |
GO:190495115 | Endometrium | AEH | positive regulation of establishment of protein localization | 74/2100 | 319/18723 | 7.05e-10 | 6.51e-08 | 74 |
GO:003133116 | Endometrium | AEH | positive regulation of cellular catabolic process | 91/2100 | 427/18723 | 9.15e-10 | 8.31e-08 | 91 |
GO:190382916 | Endometrium | AEH | positive regulation of cellular protein localization | 66/2100 | 276/18723 | 1.57e-09 | 1.36e-07 | 66 |
GO:000697916 | Endometrium | AEH | response to oxidative stress | 93/2100 | 446/18723 | 1.94e-09 | 1.64e-07 | 93 |
GO:007259410 | Endometrium | AEH | establishment of protein localization to organelle | 89/2100 | 422/18723 | 2.41e-09 | 1.90e-07 | 89 |
GO:005122215 | Endometrium | AEH | positive regulation of protein transport | 66/2100 | 303/18723 | 7.79e-08 | 3.99e-06 | 66 |
GO:006219716 | Endometrium | AEH | cellular response to chemical stress | 71/2100 | 337/18723 | 1.03e-07 | 5.05e-06 | 71 |
GO:00072296 | Endometrium | AEH | integrin-mediated signaling pathway | 32/2100 | 107/18723 | 1.24e-07 | 5.80e-06 | 32 |
GO:000166710 | Endometrium | AEH | ameboidal-type cell migration | 90/2100 | 475/18723 | 3.73e-07 | 1.57e-05 | 90 |
GO:00016498 | Endometrium | AEH | osteoblast differentiation | 52/2100 | 229/18723 | 4.74e-07 | 1.92e-05 | 52 |
GO:00506738 | Endometrium | AEH | epithelial cell proliferation | 84/2100 | 437/18723 | 4.88e-07 | 1.94e-05 | 84 |
GO:009013014 | Endometrium | AEH | tissue migration | 73/2100 | 365/18723 | 5.79e-07 | 2.20e-05 | 73 |
GO:009013214 | Endometrium | AEH | epithelium migration | 72/2100 | 360/18723 | 6.90e-07 | 2.55e-05 | 72 |
GO:001063114 | Endometrium | AEH | epithelial cell migration | 71/2100 | 357/18723 | 1.02e-06 | 3.52e-05 | 71 |
GO:003315710 | Endometrium | AEH | regulation of intracellular protein transport | 51/2100 | 229/18723 | 1.13e-06 | 3.75e-05 | 51 |
GO:00015038 | Endometrium | AEH | ossification | 78/2100 | 408/18723 | 1.54e-06 | 4.85e-05 | 78 |
GO:003238810 | Endometrium | AEH | positive regulation of intracellular transport | 46/2100 | 202/18723 | 1.96e-06 | 5.93e-05 | 46 |
GO:001063214 | Endometrium | AEH | regulation of epithelial cell migration | 60/2100 | 292/18723 | 2.31e-06 | 6.77e-05 | 60 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0520826 | Endometrium | AEH | Chemical carcinogenesis - reactive oxygen species | 91/1197 | 223/8465 | 3.28e-23 | 1.33e-21 | 9.76e-22 | 91 |
hsa0401514 | Endometrium | AEH | Rap1 signaling pathway | 49/1197 | 210/8465 | 2.03e-04 | 1.78e-03 | 1.30e-03 | 49 |
hsa05208112 | Endometrium | AEH | Chemical carcinogenesis - reactive oxygen species | 91/1197 | 223/8465 | 3.28e-23 | 1.33e-21 | 9.76e-22 | 91 |
hsa0401515 | Endometrium | AEH | Rap1 signaling pathway | 49/1197 | 210/8465 | 2.03e-04 | 1.78e-03 | 1.30e-03 | 49 |
hsa0520827 | Endometrium | EEC | Chemical carcinogenesis - reactive oxygen species | 94/1237 | 223/8465 | 4.11e-24 | 1.93e-22 | 1.44e-22 | 94 |
hsa0401522 | Endometrium | EEC | Rap1 signaling pathway | 49/1237 | 210/8465 | 4.45e-04 | 3.47e-03 | 2.59e-03 | 49 |
hsa0520836 | Endometrium | EEC | Chemical carcinogenesis - reactive oxygen species | 94/1237 | 223/8465 | 4.11e-24 | 1.93e-22 | 1.44e-22 | 94 |
hsa0401532 | Endometrium | EEC | Rap1 signaling pathway | 49/1237 | 210/8465 | 4.45e-04 | 3.47e-03 | 2.59e-03 | 49 |
hsa0520816 | Lung | IAC | Chemical carcinogenesis - reactive oxygen species | 51/1053 | 223/8465 | 8.45e-06 | 2.14e-04 | 1.42e-04 | 51 |
hsa0401510 | Lung | IAC | Rap1 signaling pathway | 41/1053 | 210/8465 | 2.01e-03 | 1.07e-02 | 7.10e-03 | 41 |
hsa0520817 | Lung | IAC | Chemical carcinogenesis - reactive oxygen species | 51/1053 | 223/8465 | 8.45e-06 | 2.14e-04 | 1.42e-04 | 51 |
hsa0401511 | Lung | IAC | Rap1 signaling pathway | 41/1053 | 210/8465 | 2.01e-03 | 1.07e-02 | 7.10e-03 | 41 |
hsa0520823 | Lung | AIS | Chemical carcinogenesis - reactive oxygen species | 47/961 | 223/8465 | 1.63e-05 | 3.77e-04 | 2.41e-04 | 47 |
hsa0401521 | Lung | AIS | Rap1 signaling pathway | 41/961 | 210/8465 | 3.23e-04 | 3.38e-03 | 2.16e-03 | 41 |
hsa0520833 | Lung | AIS | Chemical carcinogenesis - reactive oxygen species | 47/961 | 223/8465 | 1.63e-05 | 3.77e-04 | 2.41e-04 | 47 |
hsa0401531 | Lung | AIS | Rap1 signaling pathway | 41/961 | 210/8465 | 3.23e-04 | 3.38e-03 | 2.16e-03 | 41 |
hsa0520828 | Prostate | BPH | Chemical carcinogenesis - reactive oxygen species | 114/1718 | 223/8465 | 3.05e-25 | 1.44e-23 | 8.91e-24 | 114 |
hsa0401516 | Prostate | BPH | Rap1 signaling pathway | 61/1718 | 210/8465 | 1.40e-03 | 5.85e-03 | 3.62e-03 | 61 |
hsa05208113 | Prostate | BPH | Chemical carcinogenesis - reactive oxygen species | 114/1718 | 223/8465 | 3.05e-25 | 1.44e-23 | 8.91e-24 | 114 |
hsa0401517 | Prostate | BPH | Rap1 signaling pathway | 61/1718 | 210/8465 | 1.40e-03 | 5.85e-03 | 3.62e-03 | 61 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
PRKD1 | SNV | Missense_Mutation | novel | c.2745G>T | p.Glu915Asp | p.E915D | | protein_coding | tolerated_low_confidence(0.06) | benign(0.057) | TCGA-60-2698-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | mithramycin | PD |
PRKD1 | SNV | Missense_Mutation | | c.2015N>C | p.Gly672Ala | p.G672A | | protein_coding | deleterious(0.01) | probably_damaging(0.996) | TCGA-66-2744-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PRKD1 | SNV | Missense_Mutation | novel | c.2266G>T | p.Ala756Ser | p.A756S | | protein_coding | deleterious(0) | possibly_damaging(0.799) | TCGA-85-7699-01 | Lung | lung squamous cell carcinoma | Male | >=65 | III/IV | Chemotherapy | cisplatin | PD |
PRKD1 | SNV | Missense_Mutation | novel | c.2707C>G | p.Pro903Ala | p.P903A | | protein_coding | tolerated_low_confidence(0.68) | benign(0.067) | TCGA-85-8664-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Chemotherapy | carboplatin | PD |
PRKD1 | SNV | Missense_Mutation | novel | c.2411N>T | p.Ala804Val | p.A804V | | protein_coding | deleterious(0) | probably_damaging(0.981) | TCGA-90-7769-01 | Lung | lung squamous cell carcinoma | Male | <65 | I/II | Unknown | Unknown | SD |
PRKD1 | SNV | Missense_Mutation | novel | c.2434C>A | p.Pro812Thr | p.P812T | | protein_coding | tolerated(0.05) | benign(0.43) | TCGA-94-8490-01 | Lung | lung squamous cell carcinoma | Male | >=65 | I/II | Unknown | Unknown | SD |
PRKD1 | SNV | Missense_Mutation | novel | c.2611G>A | p.Glu871Lys | p.E871K | | protein_coding | deleterious(0.03) | probably_damaging(0.966) | TCGA-NC-A5HK-01 | Lung | lung squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKD1 | SNV | Missense_Mutation | novel | c.322C>T | p.Pro108Ser | p.P108S | | protein_coding | tolerated(0.39) | benign(0.373) | TCGA-BA-6869-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | III/IV | Unknown | Unknown | SD |
PRKD1 | SNV | Missense_Mutation | | c.1191C>A | p.His397Gln | p.H397Q | | protein_coding | tolerated(0.61) | benign(0) | TCGA-BA-A6DA-01 | Oral cavity | head & neck squamous cell carcinoma | Female | <65 | I/II | Chemotherapy | cisplatin | CR |
PRKD1 | SNV | Missense_Mutation | novel | c.2317N>A | p.Asp773Asn | p.D773N | | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-CN-4727-01 | Oral cavity | head & neck squamous cell carcinoma | Male | <65 | I/II | Chemotherapy | cisplatin | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | 178102596 | | |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | SOPHORETIN | QUERCETIN | |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | 249565728 | | |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | 328083472 | | |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | | RESVERATROL | RESVERATROL | 11008129 |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | CHEMBL494089 | GSK-690693 | |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | 348353640 | | |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | | VASOPRESSIN | VASOPRESSIN | 11514571 |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | CHEMBL608533 | MIDOSTAURIN | |
5587 | PRKD1 | DRUGGABLE GENOME, KINASE, ENZYME, TRANSCRIPTION FACTOR, SERINE THREONINE KINASE | inhibitor | 328083471 | | |